Dr. Essam Hamza reports

TREATMENT.COM AI INC. ANNOUNCES CLOSING OF UPSIZED BROKERED LIFE OFFERING OF UNITS

Treatment.com AI Inc., further to its news releases dated Feb. 27, 2025, and March 3, 2025, has closed its previously announced brokered private placement under the listed issuer financing exemption with Ventum Capital Corp., which acted as underwriter pursuant to an underwriting agreement dated March 13, 2025.

Dr. Essam Hamza, the chief executive officer of Treatment, added: "We would like to thank the shareholders for the strong demand shown for this financing. I would also like to thank the teams at Ventum and Treatment for all the hard work they have put into getting this significant deal across the finish line. The added money will help us expedite our ambitious growth plans and we look forward to updating the market accordingly."

Pursuant to the offering, the company issued 6.6 million units at the issue price of 50 cents per unit for gross proceeds of $3.3-million. Each unit consists of one common share in the capital of the company and one-half of one share purchase warrant of the company. Each warrant entitles the holder thereof to purchase one share at the exercise price of 75 cents until March 13, 2027.

The offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 -- Prospectus Exemptions and therefore the units issued pursuant to the offering are not subject to a hold period in accordance with applicable Canadian securities laws. There is an amended and restated offering document related to the offering that can be accessed under the company's profile at SEDAR+ and on the company's website.

Prospective investors should read this offering document before making an investment decision.

The company intends to use the proceeds from the offering for sales and administrative expenses, software research, and development and working capital purposes.

Pursuant to the underwriting agreement, the company paid to the underwriter a cash commission of $264,000 and issued 528,000 non-transferable broker warrants. Each broker warrant is exercisable for one unit at the price of 50 cents until March 13, 2027. The broker warrants and the underlying securities issued to the underwriter will be subject to a four-month-and-one-day hold period in accordance with Canadian securities laws.

About Treatment.com AI Inc.

Treatment.com AI is a company utilizing artificial and best clinical practices to positively improve the health-care sector and impact current inefficiencies and challenges. With the input of hundreds of health-care professionals globally, Treatment has built a comprehensive, personalized health-care AI engine, the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all health-care professionals, as well as providing recommended tests (physical and lab), X-rays and billing codes.

We seek Safe Harbor.